Lowest Price Guaranteed From USD 5,899
Published
March 2022
Pages
376
View Count
24388
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Over time, advances in manufacturing technologies have prompted pharmaceutical companies to shift from the traditional multi-step, batch manufacturing processes to faster and relatively efficient continuous manufacturing. Continuous manufacturing, also known as continuous flow chemistry, is an advanced manufacturing technology, which drives operations in a continuous manner (24×7) in one facility, without hold times. The concept was first described in the 1700s, for the production of pig iron in blast furnaces. Since then, the technique has been adopted by various industries, including automotive, food and beverage, oil refining, chemicals, pulp and paper, electronics, metal smelting, steel making, and waste-water treatment industries. In recent years, continuous manufacturing has gained traction in the biopharmaceutical industry as well, having captured the attention of big pharma players, as well as leading contract manufacturing organizations (CMOs). Moreover, the ongoing COVID-19 pandemic has prompted the pharmaceutical industry to shift to continuous manufacturing to scale up processing. The continuous manufacturing technology offers several benefits, including reduction in manufacturing cost (by 15-30%), manpower (by 50-70%) and power consumption (by 40%), lesser product deviation (by 50%), smaller footprint (by 50-70%) and faster scale up. Specifically, for biologics, continuous manufacturing, through upstream perfusion, is already a well-established method. In fact, more than 20 biologics manufactured using this approach have been approved by the FDA. Moreover, continuous processing technology presents a versatile and beneficial manufacturing approach for oral solid dosage (OSD) forms and small molecules as well. In the last few years, many orally administrable drugs, including TRIKAFTA® (Vertex Pharmaceuticals, 2019), DAURISMO™ (Pfizer, 2018), SYMDEKO® (Vertex Pharmaceuticals, 2018), VERZENIO® (Eli Lilly, 2017), PREZISTA® (Johnson & Johnson, 2016) and ORKAMBI® (Vertex Pharmaceuticals, 2015) manufactured using the continuous technique, have been approved by the FDA.
Presently, several technology providers / equipment suppliers are engaged in offering the necessary technologies and equipment for continuous manufacturing; these include continuous flow reactors (plug flow reactors, continuous stirred tank reactors (CSTR) and microreactors), continuous granulators, continuous coaters, continuous mixers / blenders, continuous chromatography equipment, continuous dryers and process analytical technologies (PAT). Additionally, many companies have made heavy investments in order to install this technology and expand their facilities and capabilities. Innovators in this field have received significant support in the form of grants from various administering institutes and incentives from key regulatory agencies as well. It is also important to highlight that, despite the ongoing efforts, the adoption of this technology is fraught with some challenges, including cost of equipment, process development restrictions, manufacturing of a new facility and maintenance of the equipment. However, owing to the rising interest of investors and technological advancements, we are led to believe that the opportunity for technology developers and manufacturers / users engaged in this domain is likely to grow in the foreseen future.
The “Continuous Manufacturing (Small Molecules and Biologics) Market (2nd Edition), 2022 – 2035, Distribution by Purpose of Manufacturing (In-House and Contract Services), Scale of Operation (Preclinical, Clinical and Commercial), Type of Drug Molecule (Biologic and Small Molecule), Type of Continuous Manufacturing Related Service Offered (Process Development, API Manufacturing, Intermediate Manufacturing, Drug Product Manufacturing, and Packaging and Fill / Finish), Type of Dosage Form Offered (Solid and Liquid), Installed Capacity and Geographical Regions (North America, Europe and Asia-Pacific)” report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as overall market of the currently approved drugs based on continuous manufacturing, cost of goods sold and direct manufacturing cost, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the time period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] purpose of manufacturing (in-house and contract services) [B] scale of operation (preclinical, clinical and commercial), [C] type of drug molecule (small molecule and biologic), [D] type of continuous manufacturing related service (API manufacturing and end product manufacturing), [E] type of dosage form (solid and liquid) and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). To account for the uncertainties associated with the continuous manufacturing of pharmaceuticals and biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 provides an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the pharmaceutical and biopharmaceutical continuous manufacturing market in the short to mid-term and long term.
Chapter 3 provides a general introduction to continuous flow chemistry. The chapter also includes the historical evolution of continuous manufacturing in the pharmaceutical industry. It features a brief overview of the regulatory landscape, the early adopters of this technology, advantages and key challenges associated with this technique. The chapter also discusses the future perspective of the pharmaceutical and biopharmaceutical continuous manufacturing market in this domain.
Chapter 4 provides an overview of the market landscape of companies engaged in continuous manufacturing. The chapter features information on year of establishment, company size, purpose of manufacturing (in-house and contract services), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (biologic and small molecule), type of continuous manufacturing related service offered (process development, API manufacturing, intermediate manufacturing, drug product manufacturing, and packaging and fill / finish), type of dosage form offered (solid and liquid), and installed capacity and batch size (if available).
Chapter 5 features detailed profiles of key North American players engaged in pharmaceutical and biopharmaceutical continuous manufacturing. Each profile presents a brief overview of the company, its overall contract service offerings, continuous manufacturing capabilities and facilities, recent developments and future outlook.
Chapter 6 features detailed profiles of key European players engaged in pharmaceutical and biopharmaceutical continuous manufacturing. Each profile presents a brief overview of the company, its overall contract service offerings, continuous manufacturing capabilities and facilities, recent developments and future outlook.
Chapter 7 features detailed profiles of some of key Asia-Pacific players in pharmaceutical and biopharmaceutical continuous manufacturing. Each profile presents a brief overview of the company, its overall contract service offerings, continuous manufacturing capabilities and facilities, recent developments and future outlook.
Chapter 8 features an elaborate discussion and analysis of the various collaborations established in this market, since 2013. Further, the partnership activities in this domain have been analyzed on the basis of year of agreement, the type of partnership (research agreements, facility development / establishment agreements, technology enhancement agreements, service alliances, process development agreements, manufacturing agreements and other relevant agreements) and geographical location of the players involved in the collaborations. The instances that we came across were analyzed based on various parameters including scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid).
Chapter 9 features an elaborate discussion on the various expansions that have taken place in this market, since 2013. Further, the expansion initiatives have been analyzed on the basis of year of expansion and the type of expansion (facility / plant expansion, technology installation, technology enhancement and service expansion), geographical location of the facility, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid).
Chapter 10 provides a detailed competitiveness analysis of companies having expertise in continuous manufacturing, considering various relevant parameters, such as year of experience (year of establishment - the current year), company size which comes under supplier strength, scale of production (pre-clinical, clinical and commercial) which comes under portfolio strength, type of service(s) (process development, drug substance manufacturing, intermediate manufacturing, final dosage form, packaging and labelling) and regions which comes under service applicability.
Chapter 11 features an estimate of the overall, installed capacity for manufacturing drug substances and drug products based on information reported by industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of type of drug molecule (biologic and small molecule), company size (small-sized, mid-sized and large), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific), location of manufacturing facilities (North America, Europe and Asia-Pacific).
Chapter 12 provides information on the various grants that were awarded to research institutes conducting projects related to continuous manufacturing, between 2016 and 2021. The analysis also highlights important parameters associated with grants, such as year of award, type of grant, grant amount, focus area, support period, popular recipient organizations, type of recipient organization, funding institute center, funding mechanism and prominent program officers.
Chapter 13 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to continuous manufacturing. For this analysis, we looked at the patents that have been published by various players, till 2021. The analysis highlights key details and trends associated with these patents, including patent type, publication year, geographical location, assigned CPC symbol, emerging focus area, type of applicant and leading industry / academic players (in terms of size of intellectual property portfolio). It features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach). It also includes a patent benchmarking analysis and a detailed valuation analysis.
Chapter 14 highlights initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.
Chapter 15 features a review of the companies offering modular facility / modular cleanroom with information on their geographical location (North America, Europe, Asia-Pacific and rest of the world), establishment year, size (small-sized, mid-sized or large) and type of industries served (pharmaceutical, biotechnology or others). It also includes information on the recent projects undertaken by these companies.
Chapter 16 presents a case study on the companies offering technologies / equipment (flow reactors, continuous blenders and mixers, continuous granulators, continuous compressors, continuous coaters, continuous dryers, continuous filtration, distillation and centrifugation equipment, continuous chromatography, PAT technology and other technologies) that can potentially be used in a continuous manner, providing information on the geographical location of potential stakeholders and the type of technology / equipment provided.
Chapter 17 a case study on the roadmap for the adoption of continuous manufacturing technique, discussing different strategies that can be followed by the company in order to adopt this technology or transition from batch manufacturing to continuous manufacturing.
Chapter 18 presents a comprehensive market forecast analysis, highlighting the likely growth of the pharmaceutical and biopharmaceutical continuous manufacturing market, for the time period 2022-2035. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] purpose of manufacturing (in-house and contract services) [B] scale of operation (preclinical, clinical and commercial), [C] type of drug molecule (small molecule and biologic), [D] type of continuous manufacturing related service (API manufacturing and end product manufacturing) and [E] type of dosage form (solid and liquid) and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world).
Chapter 19 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 20 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Andrea Adamo (Founder and Chief Executive Officer, Zaiput Flow Technologies), Bayan Takizawa (Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals), Eric Fang (Chief Scientific Officer, Snapdragon Chemistry), Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences), Nick Thomson (Senior Director Chemical Research and Development, Pfizer) and Ian Houson (Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde).
Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Question Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Continuous Manufacturing
3.3. Continuous Manufacturing in the Pharmaceutical Industry
3.3.1. Regulatory Landscape
3.3.2. Early Adopters of Continuous Manufacturing
3.3.3. Anticipated Shift to Continuous Manufacturing
3.3.4. Advantages of Continuous Manufacturing
3.3.5. Key Challenges Associated with Continuous Manufacturing
3.3.6. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Companies with Expertise in Continuous Manufacturing: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Purpose of Manufacturing
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Location of Headquarters
4.2.6. Analysis by Location of Continuous Manufacturing Facilities
4.2.7. Analysis by Type of Drug Molecule
4.2.8. Analysis by Type of Continuous Manufacturing Related Service
4.2.9. Analysis by Type of Dosage Form
4.2.10. Heat Map: Analysis by Company Size and Location of Headquarters
4.2.11. Information on Production Capacity
4.2.12. Logo Landscape: Analysis by Year of Establishment and Company Size
4.2.13. Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form
4.2.14. Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule
5. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES
5.1. Chapter Overview
5.2. AbbVie Contract Manufacturing
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Service Portfolio
5.2.4. Continuous Manufacturing Capabilities and Facilities
5.2.5. Recent Developments and Future Outlook
5.3. Cambrex
5.3.1. Company Overview
5.3.2. Financial Information
5.3.4. Service Portfolio
5.3.5. Continuous Manufacturing Capabilities and Facilities
5.3.6. Recent Developments and Future Outlook
5.4. Patheon (acquired by Thermo Fisher Scientific)
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Service Portfolio
5.4.4. Continuous Manufacturing Capabilities and Facilities
5.4.5. Recent Developments and Future Outlook
5.5. SK Pharmteco
5.5.1. Company Overview
5.5.2. Service Portfolio
5.5.3. Continuous Manufacturing Capabilities and Facilities
5.5.4. Recent Developments and Future Outlook
5.6. Colorcon
5.6.1. Company Overview
5.6.2. Service Portfolio
5.6.3. Continuous Manufacturing Capabilities and Facilities
5.6.4. Recent Developments and Future Outlook
6. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES
6.1. Chapter Overview
6.2. Ajinomoto Bio-Pharma Service
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Service Portfolio
6.2.4. Continuous Manufacturing Capabilities and Facilities
6.2.5. Recent Developments and Future Outlook
6.3. Almac Group
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Continuous Manufacturing Capabilities and Facilities
6.3.4. Recent Developments and Future Outlook
6.4. Boehringer Ingelheim BioXcellence™
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Service Portfolio
6.4.4. Continuous Manufacturing Capabilities and Facilities
6.4.5. Recent Developments and Future Outlook
6.5. CordonPharma
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Continuous Manufacturing Capabilities and Facilities
6.5.4. Recent Developments and Future Outlook
6.6. GEA Group
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Service portfolio
6.6.4. Continuous Manufacturing Capabilities and Facilities
6.6.5. Recent Developments and Future Outlook
6.7. Glatt Group
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Continuous Manufacturing Capabilities and Facilities
6.7.4. Recent Developments and Future Outlook
6.8. Hovione
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Continuous Manufacturing Capabilities and Facilities
6.8.4. Recent Developments and Future Outlook
6.9. Lonza
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Service Portfolio
6.9.4. Continuous Manufacturing Capabilities and Facilities
6.9.5. Recent Developments and Future Outlook
7. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES
7.1. Chapter Overview
7.2. ACG Group
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Service Portfolio
7.2.4. Continuous Manufacturing Capabilities and Facilities
7.2.5. Recent Developments and Future Outlook
7.3. Aurobindo Pharma
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Service Portfolio
7.3.4. Continuous Manufacturing Capabilities and Facilities
7.3.5. Recent Developments and Future Outlook
7.4. Kaneka
7.4.1. Company Overview
7.4.2. Financial Information
7.4.3. Service Portfolio
7.4.4. Continuous Manufacturing Capabilities and Facilities
7.4.5. Recent Developments and Future Outlook
7.5. WuXi AppTec
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Service Portfolio
7.5.4. Continuous Manufacturing Capabilities and Facilities
7.5.5. Recent Developments and Future Outlook
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Key Parameters and Methodology
8.3. Company Competitiveness Analysis
8.4. Competitiveness Analysis: Companies providing continuous manufacturing services in North America
8.5. Competitiveness Analysis: Companies providing continuous manufacturing services in Europe
8.6. Competitiveness Analysis: Companies providing continuous manufacturing services in Asia-Pacific
9. RECENT PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Scale of Operation
9.3.4. Analysis by Type of Drug Molecule
9.3.5. Analysis by Type of Continuous Manufacturing Related Service
9.3.6. Analysis by Type of Dosage Form
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Regional Analysis
9.3.8.1. Intercontinental and Intracontinental Agreements
10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Recent Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Scale of Operation
10.2.4. Analysis by Type of Drug Molecule
10.2.5. Analysis by Type of Continuous Manufacturing Related Service
10.2.6. Analysis by Type of Dosage Form
10.2.7. Most Active Players: Analysis by Number of Expansions
10.2.8. Regional Analysis
10.2.8.1. Analysis by Location of Expansion Project
11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Global, Continuous Manufacturing Capacity for Small Molecule APIs
11.3.1. Analysis by Company Size
11.3.2. Analysis by Purpose of Manufacturing
11.3.3. Analysis by Scale of Operation
11.3.4. Analysis by Location of Headquarters
11.3.4. Analysis by Location of Continuous Manufacturing Facilities
11.4. Global, Continuous Manufacturing Capacity for Small Molecule End Products
11.4.1. Analysis by Company Size
11.4.2. Analysis by Purpose of Manufacturing
11.4.3. Analysis by Scale of Operation
11.4.4. Analysis by Location of Headquarters
11.4.5. Analysis by Location of Continuous Manufacturing Facilities
11.5. Global, Continuous Manufacturing Capacity for Biologics
11.5.1. Analysis by Company Size
11.5.2. Analysis by Purpose of Manufacturing
11.5.3. Analysis by Scale of Operation
11.5.4. Analysis by Location of Headquarters
11.5.5. Analysis by Location of Continuous Manufacturing Facilities
12. ACADEMIC GRANT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Continuous Manufacturing: List of Academic Grants
12.3.1. Analysis by Number of Grants
12.3.2. Analysis by Activity Code
12.3.3. Analysis by Grant Amount
12.3.4. Analysis by Focus Area
12.3.5. Analysis by Support Period
12.3.6 Popular Recipient Organizations: Analysis by Number of Grants
12.3.7 Analysis by Type of Recipient Organization
12.3.8. Analysis by Funding Institute Center
12.3.9. Analysis by Funding Mechanism
12.3.10. Prominent Program Officers: Analysis by Number of Grants
13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Continuous Manufacturing: Patent Analysis
13.3.1. Analysis by Publication Year
13.3.2. Analysis by Geography
13.3.3. Analysis by CPC Symbols
13.3.4. Emerging Focus Areas
13.3.5. Analysis by Type of Applicant
13.3.6. Leading Players: Analysis by Number of Patents
13.3.7. Continuous Manufacturing: Three-Dimensional Bubble Analysis
13.3.8. Continuous Manufacturing: Patent Valuation Analysis
13.3.8.1. Leading Patents: Information by Number of Citations
14. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS MANUFACTURING CAPABILITIES
14.1. Chapter Overview
14.2. Continuous Manufacturing Initiatives of Leading Companies
14.2.1. AbbVie
14.2.1.1. Partnered Initiatives
14.2.1.2. In-House Initiatives
14.2.2. Amgen
14.2.2.1. Partnered Initiatives
14.2.2.2. In-House Initiatives
14.2.3. Bristol-Myers Squibb
14.2.3.1. Partnered Initiatives
14.2.3.2. In-House Initiatives
14.2.4. GlaxoSmithKline
14.2.4.1. Partnered Initiatives
14.2.4.2. In-House Initiatives
14.2.5. Merck
14.2.5.1. Partnered Initiatives
14.2.5.2. In-House Initiatives
14.2.6. Novartis
14.2.6.1. Partnered Initiatives
14.2.6.2. In-House Initiatives
14.2.7. Pfizer
14.2.7.1. Partnered Initiatives
14.2.7.2. In-House Initiatives
14.2.8. Roche
14.2.8.1. Partnered Initiatives
14.2.8.2. In-House Initiatives
14.2.9. Sanofi
14.2.9.1. Partnered Initiatives
14.2.9.2. In-House Initiatives
15. CASE STUDY: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY
15.1. Chapter Overview
15.2. Historical Background
15.3. Concept of Modularization
15.3.1. Types of Modules
15.3.2. Modular Construction Process
15.4. Modular Construction in the Pharmaceutical Industry
15.4.1. Advantages of Modular Construction in the Pharmaceutical Industry
15.5. Modular Facility Manufacturers
15.5.1. Distribution by Industry Served
15.5.2. Distribution by Geography
15.5.3. Modular Projects Executed / Undertaken
15.6. Modular Pharmaceutical Cleanrooms
15.6.1. Cleanroom Classification and Current Standards
15.6.2. Advantages of Modular Cleanrooms
15.6.3. Regulations and Standards Concerning Modular Cleanroom Construction
15.7. Modular Cleanroom Providers
15.7.1. Distribution by Industry Served
15.7.2. Distribution by Geography
15.7.3. Type of Modular Cleanrooms Offered
16. CASE STUDY: TECHNOLOGY AND EQUIPMENT PROVIDERS
16.1. Chapter Overview
16.2. Types of Continuous Manufacturing Technologies
16.3. Equipment and Technologies for Continuous Manufacturing Small Molecules and Biologics
16.3.1. Continuous Blending and Mixing Equipment
16.3.2. Continuous Granulating Equipment
16.3.3. Continuous Drying Equipment
16.3.4. Continuous Compression Equipment
16.3.5. Continuous Coating Equipment
16.3.6. Continuous Filtration, Continuous Distillation and Continuous Centrifugation Equipment
16.3.7. Continuous Chromatography Equipment
16.3.8. Continuous Reactors / Bioreactors
16.3.9. Full Line Continuous Platforms
16.3.10. Process Analytical Technologies
16.3.11. Other Technologies
16.4. Logo Landscape: Analysis of Technology Providers by Number and Type of Equipment
17. CASE STUDY: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES
17.1. Chapter Overview
17.2. Key Strategies for the Adoption of Continuous Manufacturing Processes
17.2. 1. Phase I: Process Development and Implementation
17.2. 2. Phase II: Equipment / Technology Development and Installation
17.2. 3. Phase III: Facility / Plant Development and Establishment
17.2. 4. Phase IV: Product Development and Manufacturing
18. MARKET FORECAST AND OPPORTUNITY ANALYSIS
18.1. Chapter Overview
18.2. Forecast Methodology and Key Assumptions
18.3. Overall, Continuous Manufacturing Market, 2022-2035
18.3.1. Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2022-2035
18.3.2. Continuous Manufacturing Market: Distribution by Scale of Operation, 2022-2035
18.3.3. Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2022-2035
18.3.4. Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2022-2035
18.3.5. Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2022-2035
18.3.6. Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2022-2035
18.4. Continuous Manufacturing Market for Small Molecule Drugs, 2022-2035
18.4.1. Distribution by Purpose of Manufacturing, 2022-2035
18.4.2. Distribution by Scale of Operation, 2022-2035
18.4.3. Distribution by Type of Continuous Manufacturing Related Service, 2022-2035
18.4.4. Distribution by Key Geographical Regions, 2022-2035
18.5. Continuous Manufacturing Market for Biologics, 2022-2035
18.5.1. Distribution by Purpose of Manufacturing, 2022-2035
18.5.2. Distribution by Scale of Operation, 2022-2035
18.5.3. Distribution by Type of Continuous Manufacturing Related Service, 2022-2035
18.5.4. Distribution by Key Geographical Regions, 2022-2035
19. CONCLUSION
19.1. Chapter Overview
20. EXECUTIVE INSIGHTS
20.1. Chapter Overview
20.2. Zaiput Flow Technologies
20.2.1. Company Snapshot
20.2.2. Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer
20.3. CONTINUUS Pharmaceuticals
20.3.1. Company Snapshot
20.3.2. Interview Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer
20.4. Snapdragon Chemistry
20.4.1. Company Snapshot
20.4.2. Interview Transcript: Eric Fang, Chief Scientific Officer
20.5. Enzene Biosciences
20.5.1. Company Snapshot
20.5.2. Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer
20.6. Pfizer
20.6.1. Company Snapshot
20.6.2. Interview Transcript: Nick Thomson, Senior Director Chemical Research and Development
20.7. University of Strathclyde
20.7.1. Company Snapshot
20.7.2. Interview Transcript: Ian Houson, Technical Project Manager
21. APPENDIX 1: TABULATED DATA
22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 4.1 Continuous Drug Manufacturers: Distribution by Year of Establishment
Figure 4.2 Continuous Drug Manufacturers: Distribution by Company Size
Figure 4.3 Continuous Drug Manufacturers: Distribution by Purpose of Manufacturing
Figure 4.4 Continuous Drug Manufacturers: Distribution by Scale of Operation
Figure 4.5 Continuous Drug Manufacturers: Distribution by Location of Headquarters
Figure 4.6 Continuous Drug Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Figure 4.7 Continuous Drug Manufacturers: Distribution by Type of Drug Molecule
Figure 4.8 Continuous Drug Manufacturers: Distribution by Type of Continuous Manufacturing Related Service
Figure 4.9 Continuous Drug Manufacturers: Distribution by Type of Dosage Form
Figure 4.10 Continuous Drug Manufacturers: Distribution by Year of Establishment and Type of Company Size
Figure 4.11 Continuous Drug Manufacturers: Distribution by Scale of Operation, Type of Continuous Manufacturing related Service Offered and Type of Dosage Form
Figure 4.12 Continuous Drug Manufacturers: Distribution by Location of Continuous Manufacturing Facility and Type of Drug Molecule Manufactured
Figure 5.1 AbbVie: Annual Revenues, 2014-2021 (USD Billion)
Figure 5.2 AbbVie Contract Manufacturing: Services Portfolio
Figure 5.3 Cambrex: Annual Revenues, 2014 – 9M 2019 (USD Million)
Figure 5.4 Cambrex: Services Portfolio
Figure 5.5 Thermo Fisher Scientific: Annual Revenues, 2014 – H1 2021 (USD Million)
Figure 5.7 SK Pharmteco: Service Portfolio
Figure 5.8. Colorcon: Service Portfolio
Figure 6.1 Ajinomoto Bio-Pharma Services: Annual Revenues, FY 2014 - FY 2021 (JPY Billion)
Figure 6.2 Ajinomoto Bio-Pharma Service: Services Portfolio
Figure 6.3 Almac: Service Portfolio
Figure 6.4 Boehringer Ingelheim: Annual Revenues, 2014- H1 2021 (EUR Billion)
Figure 6.5 Boehringer Ingelheim BioXcellence: Service Portfolio
Figure 6.7 Hovione: Service Portfolio
Figure 6.8 Lonza: Annual Revenues, 2014-2021 (CHF Billion)
Figure 6.9 Lonza: Service Portfolio
Figure 6.10 Glatt Pharma: service Portfolio
Figure 6.11 GEA Group: Annual Revenues, FY 2014 – Q1 2021 (EURP Million)
Figure 6.12 GEA Group: Service Portfolio
Figure 7.1 Kaneka: Annual Revenues, FY 2014 – Q1 2021 (JPY Billion)
Figure 7.2 Kaneka: Service Portfolio
Figure 7.3 WuXi AppTec: Annual Revenues, 2015 – H1 2021 (RMB Million)
Figure 7.4 WuXi Biologics: Service Portfolio
Figure 7.5 STA Pharmaceuticals: Service Portfolio
Figure 7.6. ACG Group: Annual Revenues, FY 2014 – Q1 2021 (YEN Million)
Figure 7.7 ACG Group: Service Portfolio
Figure 7.8 Aurobindo Pharma: Annual Revenues, FY 2014 – FY 2021
Figure 7.9 Aurobindo Pharma: Service Portfolio
Figure 8.1 Company Competitiveness Analysis: Continuous Manufacturing Service in North America
Figure 8.2 Company Competitiveness Analysis: Continuous Manufacturing Service in Europe
Figure 8.3 Company Competitiveness Analysis: Continuous Manufacturing Service in Asia Pacific
Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2021
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2013-2021
Figure 9.4. Partnerships and Collaborations: Distribution by Type of Partnership, 2013-2015 and 2016-2021
Figure 9.5. Partnerships and Collaborations: Distribution by Scale of Operation
Figure 9.6. Partnerships and Collaborations: Distribution by Type of Drug Molecule
Figure 9.7. Partnerships and Collaborations: Distribution Type of Continuous Manufacturing Related Service
Figure 9.8. Partnerships and Collaborations: Distribution by Type of Dosage Form
Figure 9.9. Most Active Players: Distribution by Number of Partnerships
Figure 9.10. Partnerships and Collaborations: Regional Distribution
Figure 9.11. Partnerships and Collaborations: Intercontinental and IntracontinentalAgreements
Figure 10.1. Recent Expansions: Cumulative Year-wise Trend, 2013- November 2021
Figure 10.2. Recent Expansions: Distribution by Type of Expansion
Figure 10.3. Recent Expansions: Distribution by Scale of Operation and Year of Expansion Figure 10.4.Recent Expansions: Distribution by Type of Drug Molecule
Figure 10.5. Recent Expansions: Distribution by Type of Continuous Manufacturing Related Service
Figure 10.6. Recent Expansions: Distribution by Type of Dosage Form
Figure 10.7. Most Active Players: Distribution by Number of Expansions
Figure 10.8. Recent Expansions: Intercontinental and Intracontinental Distribution
Figure 10.9. Recent Expansions: Regional Distribution
Figure 11.1 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Geographical Location
Figure 11.2 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Company Size (Range of Capacity)
Figure 11.3 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Company Size (in Metric Tonnes / Year)
Figure 11.4 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Purpose of Manufacturing (in Metric Tonnes / Year)
Figure 11.5 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Scale of Operation (in Metric Tonnes / Year)
Figure 11.6 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Headquarters (in Metric Tonnes / Year)
Figure 11.7 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Continuous Manufacturing Facilities (in Metric Tonnes / Year)
Figure 11.8 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Geographical Location
Figure 11.9 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Company Size (Range of Capacity)
Figure 11.10 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Company Size (in Kgs / Year)
Figure 11.11 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Purpose of Manufacturing (in Kgs / Year)
Figure 11.12 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Scale of Operation (in Kgs / Year)
Figure 11.13 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Headquarters (in Kgs / Year)
Figure 11.14 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
Figure 11.15 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Geographical Location
Figure 11.16 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Company Size (Range of Capacity)
Figure 11.17 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Company Size (in Kgs / Year)
Figure 11.18 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Purpose of Manufacturing (in Kgs / Year)
Figure 11.19 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Scale of Operation (in Kgs / Year)
Figure 11.20 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Headquarters (in Kgs / Year)
Figure 11.21 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
Figure 12.1 Academic Grant Analysis: Cumulative Year-wise Trend, 2014-2019
Figure 12.2 Academic Grant Analysis: Distribution by Activity Codes
Figure 12.3 Academic Grant Analysis: Year-wise Distribution by Leading Activity Codes
Figure 12.4 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 12.5 Academic Grant Analysis: Distribution by Focus Areas
Figure 12.6 Academic Grant Analysis: Distribution by Support Period
Figure 12.7 Popular Recipient Organizations: Distribution by States in the US
Figure 12.8 Popular Recipient Organizations: Distribution by Number of Grants
Figure 12.9 Popular Recipient Organizations: Distribution by Amount Awarded
Figure 12.10 Academic Grant Analysis: Distribution by Type of Recipient Organization
Figure 12.11 Academic Grant Analysis: Distribution by Support Year and Funding Institute Centre
Figure 12.12 Academic Grant Analysis: Distribution by Funding Mechanism
Figure 12.13 Prominent Program Officers: Distribution by Number of Grants
Figure 13.1 Patent Portfolio: Distribution by Type of Patent
Figure 13.2 Patent Portfolio: Cumulative Year-wise Trend, till 2019
Figure 13.3 Patent Portfolio: Cumulative Year-wise Trend, till 2021 (forPharmaceutical and Biopharmaceutical Industry)
Figure 13.4 Patent Portfolio: Distribution by Geography
Figure 13.5 Patent Portfolio: Distribution by CPC Symbols
Figure 13.6 Patent Portfolio: Distribution of CPC Symbols by Publication Year
Figure 13.7 Patent Portfolio: Emerging Focus Areas
Figure 13.8 Patent Portfolio: Distribution by Type of Applicant
Figure 13.9 Leading Industry Players: Distribution by Number of Patents
Figure 13.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 13.11 Patent Portfolio: Three-Dimensional Bubble Analysis
Figure 13.12 Patent Portfolio: Distribution by Patent Age, 2000-2021
Figure 13.13 Patent Portfolio: Distribution by Geography, Before 2014-2021
Figure 13.14 Patent Portfolio: Valuation Analysis
Figure 14.1 Continuous Manufacturing Initiatives: AbbVie
Figure 14.2 Continuous Manufacturing Initiatives: Amgen
Figure 14.3 Continuous Manufacturing Initiatives: Bristol-Myers Squibb
Figure 14.4 Continuous Manufacturing Initiatives: GlaxoSmithKline
Figure 14.5 Continuous Manufacturing Initiatives: Merck
Figure 14.6 Continuous Manufacturing Initiatives: Novartis
Figure 14.7 Continuous Manufacturing Initiatives: Pfizer
Figure 14.8 Continuous Manufacturing Initiatives: Roche
Figure 14.9 Continuous Manufacturing Initiatives: Sanofi
Figure 15.1 Modular Construction: Applications
Figure 15.2 Modular Construction: Processes Involved
Figure 15.3 Modular and Conventional Buildings: Construction Timelines
Figure 15.4 Modular Construction: Advantages
Figure 15.5 Modular Facility Manufacturers: Distribution by Geography
Figure 15.6 Modular Cleanroom Providers: Distribution by Geography
Figure 16.1 Type of Continuous Manufacturing Technologies: Hybrid vs Fully Integrated Continuous Technologies
Figure 16.2 Logo Landscape: Distribution of Technology / Equipment Providers by Number and Type of Equipment / Technology
Figure 17.1 Continuous Manufacturing: Key Strategies for the Adoption of Continuous Manufacturing Processes
Figure 17.2 Process Development and Implementation (Phase I): Distribution by Type of Strategies Adopted
Figure 17.3 Equipment / Technology Development and Installation (Phase II): Distribution by the Type of Strategies Adopted
Figure 17.4 Facility / Plant Development and Establishment (Phase III): Distribution by the Type of Strategies Adopted
Figure 17.5 Product Development and Manufacturing (Phase IV): Distribution by the Type of Strategies Adopted
Figure 18.1 Continuous Manufacturing, 2022-2035: Standard Adoption Curve
Figure 18.2. Overall, Continuous Manufacturing Market, 2022-2035 (USD Million)
Figure 18.3. Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
Figure 18.4. Continuous Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 18.5. Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2022-2035 (USD Million)
Figure 18.6. Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2022-2035 (USD Million)
Figure 18.7. Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2022-2035 (USD Million)
Figure 18.8. Continuous Manufacturing Market: Distribution by Geographical Regions 2022-2035 (USD Million)
Figure 18.9 Continuous Manufacturing Market for Small Molecules: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
Figure 18.10 Continuous Manufacturing Market for Small Molecule: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 18.11 Continuous Manufacturing Market for Small Molecule: Distribution by Type of Continuous Manufacturing Related Service, 2022-2035 (USD Million)
Figure 18.12 Continuous Manufacturing Market for Small Molecule: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 18.13 Continuous Manufacturing Market for Biologic: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
Figure 18.14 Continuous Manufacturing Market for Biologic: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 18.15 Continuous Manufacturing Market for Biologic: Distribution by Type of Continuous Manufacturing Related Service, 2022-2035 (USD Million)
Figure 18 .16 Continuous Manufacturing Market for Biologic: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 3.1 Comparison of Characteristics: Batch Manufacturing Technique and Continuous Manufacturing Technique
Table 4.1 List of Companies with Expertise in Continuous Drug Manufacturing
Table 4.2 Continuous Drug Manufacturers: Information on Location and Number of Continuous Drug Manufacturing Facilities
Table 4.3 Continuous Drug Manufacturers: Information on Type of Drug Molecule
Table 4.4 Continuous Drug Manufacturers: Information on Type of Continuous Manufacturing Related Service
Table 4.5 Continuous Drug Manufacturers: Information on Type of Dosage Form
Table 4.6 Continuous Drug Manufacturers: Distribution by Company Size and Location of Headquarters
Table 4.7 Continuous Drug Manufacturers: Information on Production Capacity
Table 5.1 Companies profiled in North America
Table 5.2 AbbVie: Company Snapshot
Table 5.3 AbbVie Contract Manufacturing: Continuous Manufacturing Facilities
Table 5.4 AbbVie Contract Manufacturing: Continuous Manufacturing Capabilities
Table 5.5 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
Table 5.6 Cambrex: Company Snapshot
Table 5.7 Cambrex: Continuous Manufacturing Facilities
Table 5.8 Cambrex: Continuous Manufacturing Capabilities
Table 5.9 Cambrex: Recent Developments and Future Outlook
Table 5.10 Patheon: Company Snapshot
Table 5.11 Patheon: Continuous Manufacturing Facilities
Table 5.12 Patheon: Continuous Manufacturing Capabilities
Table 5.13 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 5.14 SK Pharmteco: Company Snapshot
Table 5.15 SK Pharmteco: Continuous Manufacturing Facilities
Table 5.16 SK Pharmteco: Continuous Manufacturing Capabilities
Table 5.17 SK Pharmteco: Recent Developments and Future Outlook
Table 5.18 Colorcon: Company Overview
Table 5.19 Colorcon: Continuous Manufacturing Facilities
Table 5.20 Colorcon: Continuous Manufacturing Capabilities
Table 5.21 Colorcon: Recent Developments and Future Outlook
Table 6.1 Companies Profiled in Europe
Table 6.2 Ajinomoto Bio-Pharma Services: Company Snapshot
Table 6.3 Ajinomoto Bio-Pharma Services: Continuous Manufacturing Facilities
Table 6.4 Ajinomoto Bio-Pharma Services: Continuous Manufacturing Capabilities
Table 6.5 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
Table 6.6 Almac: Company Snapshot
Table 6.7 Almac: Continuous Manufacturing Facilities
Table 6.8 Almac: Continuous Manufacturing Capabilities
Table 6.9 Almac: Recent Developments and Future Outlook
Table 6.10 Boehringer Ingelheim BioXcellence™: Company Snapshot
Table 6.11 Boehringer Ingelheim BioXcellence™: Continuous Manufacturing Facilities
Table 6.12 Boehringer Ingelheim BioXcellence™: Continuous Manufacturing Capabilities
Table 6.13 Boehringer Ingelheim BioXcellence™: Recent Developments and Future Outlook
Table 6.14 CordonPharma: Company Snapshot
Table 6.15 CordonPharma: Continuous Manufacturing Facilities
Table 6.16 CordonPharma: Continuous Manufacturing Capabilities
Table 6.17 CordonPharma: Recent Developments and Future Outlook
Table 6.18 Hovione: Company Snapshot
Table 6.19 Hovione: Continuous Manufacturing Facilities
Table 6.20 Hovione: Continuous Manufacturing Capabilities
Table 6.21 Hovione: Recent Developments and Future Outlook
Table 6.22 Lonza: Company Snapshot
Table 6.23 Lonza: Continuous Manufacturing Facilities
Table 6.24 Lonza: Continuous Manufacturing Capabilities
Table 6.25 Lonza: Recent Developments and Future Outlook
Table 6.22 Glatt Pharma: Company Snapshot
Table 6.23 Glatt Pharma: Continuous Manufacturing Facilities
Table 6.24 Glatt Pharma: Continuous Manufacturing Capabilities
Table 6.25 Glatt Pharma: Recent Developments and Future Outlook
Table 6.22 GEA Group: Company Snapshot
Table 6.23 GEA Group: Continuous Manufacturing Capabilities
Table 6.24 GEA Group: Recent Developments and Future Outlook
Table 7.1 Companies Profiled in Asia-Pacific
Table 7.2 Kaneka: Company Snapshot
Table 7.3 Kaneka: Continuous Manufacturing Facilities
Table 7.4 Kaneka: Continuous Manufacturing Capabilities
Table 7.5 Kaneka: Recent Developments and Future Outlook
Table 7.6 WuXi Biologics: Company Overview
Table 7.7 STA Pharmaceuticals: Company Overview
Table 7.8 WuXi Biologics: Continuous Manufacturing Facilities
Table 7.9 WuXi Biologics: Continuous Manufacturing Capabilities
Table 7.10 STA Pharmaceuticals: Continuous Manufacturing Facilities
Table 7.11 STA Pharmaceuticals: Continuous Manufacturing Capabilities
Table 7.12 WuXi Apptec: Future Outlook
Table 7.13 ACG Group: Company Snapshot
Table 7.14 ACG Group: Continuous Manufacturing Facilities
Table 7.15 ACG Group: Continuous Manufacturing Capabilities
Table 7.16 ACG Group: Recent Developments and Future Outlook
Table 7.17 Aurobindo Pharma: Company Snapshot
Table 7.18 Aurobindo Pharma: Continuous Manufacturing Facilities
Table 7.19 Aurobindo Pharma: Continuous Manufacturing Capabilities
Table 7.20 Aurobindo Pharma: Recent Developments and Future Outlook
Table 8.1 Continuous Manufacturing: List of Partnerships and Collaborations, 2013-2021
Table 8.2 Continuous Manufacturing: Information on Scale of Production, Type of Drug Molecule, Continuous Manufacturing Related Services and Type of Drug Product, 2013- 2021
Table 9.1 Continuous Manufacturing: List of Recent Expansions, 2013 – November 2021
Table 9.2 Continuous Manufacturing: Information on Scale of Production, Type of Drug Molecule, Continuous Manufacturing Related Services and Type of Drug Product, 2013 - November 2021
Table 10.1 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Average Capacity by Company Size (Sample Data Set)
Table 10.2 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Average Capacity by Company Size (Sample Data Set)
Table 10.3 Global, Overall Continuous Manufacturing Capacity for Biologics (Kgs / Year): Average Capacity by Company Size (Sample Data Set)
Table 11.1 Continuous Manufacturing: List of Academic Grants, 2014-2021
Table 12.1 Patent Portfolio: CPC Symbols
Table 12.2 Patent Portfolio: Most Popular CPC Symbols
Table 12.3 Patent Portfolio: List of Top CPC symbols
Table 12.4 Patent Valuation Analysis: Categorization based on Proprietary Scoring Criteria
Table 12.5 Patent Portfolio: Distribution by Number of Citations
Table 13.1 AbbVie: Partnered Initiatives
Table 13.2 AbbVie: In-House Initiatives
Table 13.3 Amgen: Partnered Initiatives
Table 13.4 Amgen: In-House Initiatives
Table 13.5 Bristol-Myers Squibb: Partnered Initiatives
Table 13.6 Bristol-Myers Squibb: In-House Initiatives
Table 13.7 GlaxoSmithKline: Partnered Initiatives
Table 13.8 GlaxoSmithKline: In-House Initiatives
Table 13.9 Merck: Partnered Initiatives
Table 13.10 Merck: In-House Initiatives
Table 13.11 Novartis: Partnered Initiatives
Table 13.12 Novartis: In-House Initiatives
Table 13.13 Pfizer: Partnered Initiatives
Table 13.14 Pfizer: In-House Initiatives
Table 13.15 Roche: Partnered Initiatives
Table 13.16 Roche: In-House Initiatives
Table 13.17 Sanofi: Partnered Initiatives
Table 13.18 Sanofi: In-House Initiatives
Table 14.1 List of Modular Facility Manufacturers
Table 14.2 Modular Facility Manufacturers: Information on Type of Industry Served
Table 14.3 Modular Facility Manufacturers: Modular Projects Executed / Undertaken
Table 14.4 Cleanrooms Classification Standards
Table 14.5 ISO and FED STD 209E: Cleanroom Classification
Table 14.6 List of Modular Cleanroom Providers
Table 14.7 Modular Cleanroom Providers: Information on Type of Industry Served
Table 14.8 Modular Cleanroom Providers: Information on Type of Modular Cleanroom Offered
Table 15.1 Technology and Equipment Providers: List of Continuous Blending and Mixing Equipment
Table 15.2 Technology and Equipment Providers: List of Continuous Granulating Equipment
Table 15.3 Technology and Equipment Providers: List of Continuous Drying Equipment
Table 15.4 Technology and Equipment Providers: List of Continuous Compression Equipment
Table 15.5 Technology and Equipment Providers: List of Continuous Coating Equipment
Table 15.6 Technologies and Equipment Providers: List of Continuous Filtration, Distillation and Centrifugation Equipment
Table 15.7 Technologies and Equipment Providers: List of Continuous Chromatography Equipment
Table 15.8 Technologies and Equipment Providers: List of Continuous Flow Reactors / Bioreactors
Table 15.9 Technology and Equipment Providers: List of Full Line Continuous Platforms
Table 15.10 Technology and Equipment Providers: List of Process Analytical Technologies
Table 15.11 Technology and Equipment Providers: List of Other Technologies
Table 18.1 Continuous Manufacturing Market: Key Takeaways
Table 19.1 Zaiput Flow Technologies: Key Highlights
Table 19.2 CONTINUUS Pharmaceuticals: Key Highlights
Table 19.3 Snapdragon Chemistry: Key Highlights
Table 19.4 Enzene Biosciences: Key Highlights
Table 19.5 Pfizer: Key Highlights
Table 19.6 University of Strathclyde: Key Highlights
Table 20.1 Continuous Drug Manufacturers: Distribution by Year of Establishment
Table 20.2 Continuous Drug Manufacturers: Distribution by Company Size
Table 20.3 Continuous Drug Manufacturers: Distribution by Purpose of Manufacturing
Table 20.4 Continuous Drug Manufacturers: Distribution by Scale of Operation
Table 20.5 Continuous Drug Manufacturers: Distribution by Location of Headquarters
Table 20.6 Continuous Drug Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Table 20.7 Continuous Drug Manufacturers: Distribution by Type of Drug Molecule
Table 20.8 Continuous Drug Manufacturers: Distribution by Type of Continuous Manufacturing Related Service
Table 20.9 Continuous Drug Manufacturers: Distribution by Type of Dosage Form
Table 20.10 AbbVie: Annual Revenues, 2014–2021 (USD Billion)
Table 20.11 Cambrex: Annual Revenues, 2014-9M 2019 (USD Million)
Table 20.12 Thermo Fisher Scientific Patheon: Annual Revenues, 2014 – H1 2021 (USD Million)
Table 20.13 Ajinomoto Bio-Pharma Services: Annual Revenues, FY 2014 – Q1 2021 Revenue (JPY Billion)
Table 20.14 Boehringer Ingelheim: Annual Revenues, 2014 - 2021, (EUR Billion)
Table 20.15 Lonza: Annual Revenues, 2014 – H1 2021 (CHF Billion)
Table 20.16 GEA Group: Annual Revenues, FY 2014 – Q1 2021 (EURP Million)
Table 20.17 Kaneka: Annual Revenues, FY 2014 – Q1 2021, (JPY Billion)
Table 20.18 WuXi Apptec: Annual Revenues, 2015 – H1 2021 (RMB Million)
Table 20.19 ACG Group: Annual Revenues, FY 2014 – Q1 2021 (YEN Million)
Table 20.20 Aurobindo Pharma: Annual Revenues, FY 2014 – FY 2021
Table 20.21 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2021
Table 20.22 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.23 Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2013-2021
Table 20.24 Partnerships and Collaborations: Distribution by Type of Partnership, 2013 - 2015 and 2016-2021
Table 20.25 Partnerships and Collaborations: Distribution by Scale of Operation
Table 20.26 Partnerships and Collaborations: Distribution by Type of Drug Molecule
Table 20.27 Partnerships and Collaborations: Distribution by Type of Continuous Manufacturing Related Service
Table 20.28 Partnerships and Collaborations: Distribution by Type of Dosage Form
Table 20.29 Most Active Players: Distribution by Number of Partnerships
Table 20.30 Partnerships and Collaborations: Regional Distribution
Table 20.31 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 20.32 Recent Expansions: Cumulative Year-wise Trend, 2013- January 2021
Table 20.33 Recent Expansions: Distribution by Type of Expansion
Table 20.34 Recent Expansions: Distribution by Type of Drug Molecule
Table 20.35 Recent Expansions: Distribution by Type of Continuous Manufacturing Related Service
Table 20.36 Recent Expansions: Distribution by Type of Dosage Form
Table 20.37 Most Active Players: Distribution by Number of Expansions
Table 20.38 Recent Expansions: Intercontinental and Intracontinental Distribution
Table 20.39 Recent Expansions: Regional Distribution
Table 20.40 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Company Size (in Metric Tonnes / Year)
Table 20.41 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Purpose of Manufacturing (in Metric Tonnes / Year)
Table 20.42 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Scale of Operation (in Metric Tonnes / Year)
Table 20.43 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Headquarters (in Metric Tonnes / Year)
Table 20.44 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Continuous Manufacturing Facilities (in Metric Tonnes / Year)
Table 20.45 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Company Size (in Kgs / Year)
Table 20.46 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Purpose of Manufacturing (in Kgs / Year)
Table 20.47 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Scale of Operation (in Kgs / Year)
Table 20.48 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Headquarters (in Kgs / Year)
Table 20.49 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
Table 20.50 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Company Size (in Kgs / Year)
Table 20.51 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Purpose of Manufacturing (in Kgs / Year)
Table 20.52 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Scale of Operation (in Kgs / Year)
Table 20.53 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Headquarters (in Kgs / Year)
Table 20.54 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
Table 20.55 Academic Grant Analysis: Cumulative Year-wise Trend, 2016-2021
Table 20.56 Academic Grant Analysis: Distribution by Activity Codes
Table 20.57 Academic Grant Analysis: Year-wise Distribution on Leading Activity Codes
Table 20.58 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 20.59 Academic Grant Analysis: Distribution by Support Period
Table 20.60 Popular Recipient Organizations: Distribution by Number of Grants
Table 20.61 Popular Recipient Organizations: Distribution by Amount Awarded (USD Million)
Table 20.62 Academic Grant Analysis: Distribution by Type of Recipient Organization
Table 20.63 Academic Grant Analysis: Distribution by Support Year and Funding Institute Centre
Table 20.64 Academic Grant Analysis: Distribution by Funding Mechanism
Table 20.65 Prominent Program Officers: Distribution by Number of Grants
Table 20.66 Patent Portfolio: Distribution by Type of Patent
Table 20.67 Patent Portfolio: Cumulative Year-wise Trend, till 2021
Table 20.68 Patent Portfolio: Cumulative Year-wise Trend, till 2021 (Pharmaceutical and Biopharmaceutical Industry)
Table 20.69 Patent Portfolio: Distribution by Geography
Table 20.70 Patent Portfolio: Distribution of CPC Symbols by Publication Year (Before 2014-2021)
Table 20.71 Patent Portfolio: Distribution by Type of Applicant
Table 20.72 Leading Industry Players: Distribution by Number of Patents
Table 20.73 Leading Non-Industry Players: Distribution by Number of Patents
Table 20.74 Patent Portfolio: Distribution of Patents by Age, 2000-2021
Table 20.75 Patent Portfolio: Distribution of Patents by Geography, Before 2014-2021
Table 20.76 Continuous Manufacturing, 2022-2035: Year-Wise Adoption Curve by Type of Molecule and Manufacturing Service (%)
Table 20.77 Overall, Continuous Manufacturing Market, 2022-2035 (USD Million)
Table 20.78 Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
Table 20.79 Continuous Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 20.80 Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2022-2035 (USD Million)
Table 20.81 Continuous Manufacturing Market (Small Molecules and Biologics): Distribution by Type of Continuous Manufacturing Related Service, 2022-2035 (USD Million)
Table 20.82 Continuous Manufacturing Market (Small Molecules and Biologics): Distribution by Type of Dosage Form, 2022-2035 (USD Million)
Table 20.83 Continuous Manufacturing Market (Small Molecules and Biologics): Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 20.84 Continuous Manufacturing Market for Small Molecule: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
Table 20.85 Continuous Manufacturing Market for Small Molecule: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 20.86 Continuous Manufacturing Market for Small Molecule: Distribution by Type of Continuous Manufacturing Related Services, 2022-2035 (USD Million)
Table 20.87 Continuous Manufacturing Market for Small Molecule: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 20.88 Continuous Manufacturing Market for Biologic: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
Table 20.89 Continuous Manufacturing Market for Biologic: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 20.90 Continuous Manufacturing Market for Biologic: Distribution by Type of Continuous Manufacturing Related Service, 2022-2035 (USD Million)
Table 20.91 Continuous Manufacturing Market for Biologic: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Discounts available for multiple report purchases
sales@rootsanalysis.com